- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
This is an old revision of the document!
Applications to the FDA for orphan drug status for Marshall Protocol medications
Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. has submitted multiple applications to the Office of Orphan Products Development, a division of the FDA. The goal of submitting these applications would be to make it easier for doctors to prescribe and harder for insurance companies to deny coverage of MP medications.
Minocycline
- submitted by ARF (September 2005) - Application for Orphan Drug Status for minocycline in sarcoidosis
- FDA approval (March 2006) - minocycline as an orphan drug for sarcoidosis
Clindamycin
- submitted by ARF (September 2005) - Application for Orphan Drug Status for clindamycin in treatment of sarcoidosis and Post-Treatment Lyme Disease Syndrome
- FDA approval (August 2006) - clindamycin as an orphan drug for sarcoidosis
<html> <!–
Olmesartan
- submitted by ARF (July 2006) - Application for Orphan Drug Status for olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. in treatment of Post-Treatment Lyme Disease Syndrome
- application pending
–!</html>
home/publications/applications_orphan_status.1299443561.txt.gz · Last modified: 04.24.2011 (external edit)
© 2015, Autoimmunity Research Foundation. All Rights Reserved.